# Anti-Xa Level With Thromboprophylactic Dosage Nadroparin in Critically Ill COVID-19 and Non-COVID-19 Patients

> **NCT05926518** · — · COMPLETED · sponsor: **Rijnstate Hospital** · enrollment: 62 (actual)

## Conditions studied

- Critical Illness
- Therapeutic Drug Monitoring
- Venous Thromboembolism

## Interventions

- **PROCEDURE:** blood sampling

## Key facts

- **NCT ID:** NCT05926518
- **Lead sponsor:** Rijnstate Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-01
- **Primary completion:** 2022-04-01
- **Final completion:** 2022-11-23
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05926518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05926518, "Anti-Xa Level With Thromboprophylactic Dosage Nadroparin in Critically Ill COVID-19 and Non-COVID-19 Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05926518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*